MATINAS BIOPHARMA HOLDINGS, INC. Preferred Stock Dividends and Other Adjustments
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Preferred Stock Dividends and Other Adjustments of $396.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsAndOtherAdjustments · last filed 2023-03-15
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for the quarter ending 2021-12-31 was $201.00, a 99.91% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for the quarter ending 2021-06-30 was $184.90K, a 4.41% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for the quarter ending 2021-03-31 was $210.90K, a 23.55% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for fiscal 2021 was $396.00K, a 50.09% decline from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for fiscal 2020 was $793.44K, a 134.32% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for fiscal 2019 was $338.61K, a 42.38% decline from fiscal 2018.
- MATINAS BIOPHARMA HOLDINGS, INC. preferred stock dividends and other adjustments for fiscal 2018 was $587.64K, a 3.40% decline from fiscal 2017.
| Period end | Preferred Stock Dividends and Other Adjustments 3 month | Preferred Stock Dividends and Other Adjustments 6 month | Preferred Stock Dividends and Other Adjustments 9 month | Preferred Stock Dividends and Other Adjustments 12 month | Preferred Stock Dividends and Other Adjustments 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $201.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $201.00 derived: sum of 2 quarters · filed 2023-03-15 | $185.10K derived: sum of 3 quarters · filed 2023-03-15 | $396.00K 10-K · filed 2023-03-15 | $395.80K 10-K · filed 2022-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $184.90K derived: sum of 2 quarters · filed 2022-11-02 | $395.80K 10-Q · filed 2022-11-02 | $613.85K derived: sum of 4 quarters · filed 2022-11-02 | |
| 2021-06-30 | $184.90K 10-Q · filed 2022-08-11 | $395.80K 10-Q · filed 2022-08-11 | $613.85K derived: sum of 3 quarters · filed 2022-08-11 | $841.45K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $210.90K 10-Q · filed 2022-05-12 | $428.95K derived: sum of 2 quarters · filed 2022-05-12 | $656.55K derived: sum of 3 quarters · filed 2022-05-12 | $833.64K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $218.05K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $445.65K derived: sum of 2 quarters · filed 2022-03-11 | $622.74K derived: sum of 3 quarters · filed 2022-03-11 | $793.44K 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | $227.60K 10-Q · filed 2021-11-08 | $404.69K derived: sum of 2 quarters · filed 2021-11-08 | $575.39K 10-Q · filed 2021-11-08 | $575.39K derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | $177.09K 10-Q · filed 2021-08-10 | $347.79K 10-Q · filed 2021-08-10 | $347.79K derived: sum of 3 quarters · filed 2021-08-10 | $392.83K derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | $170.70K 10-Q · filed 2021-05-10 | $170.70K derived: sum of 2 quarters · filed 2021-05-10 | $215.74K derived: sum of 3 quarters · filed 2021-05-10 | $362.53K derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $45.04K derived: sum of 2 quarters · filed 2021-03-29 | $191.83K derived: sum of 3 quarters · filed 2021-03-29 | $338.61K 10-K · filed 2021-03-29 | |
| 2019-09-30 | $45.04K 10-Q · filed 2020-11-06 | $191.83K derived: sum of 2 quarters · filed 2020-11-06 | $338.61K 10-Q · filed 2020-11-06 | $485.40K derived: sum of 4 quarters · filed 2020-11-06 | |
| 2019-06-30 | $146.79K 10-Q · filed 2020-08-10 | $293.57K 10-Q · filed 2020-08-10 | $440.36K derived: sum of 3 quarters · filed 2020-08-10 | $587.14K derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $146.79K 10-Q · filed 2020-05-11 | $293.57K derived: sum of 2 quarters · filed 2020-05-11 | $440.36K derived: sum of 3 quarters · filed 2020-05-11 | $587.14K derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $146.79K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $293.57K derived: sum of 2 quarters · filed 2020-03-09 | $440.36K derived: sum of 3 quarters · filed 2020-03-09 | $587.64K 10-K · filed 2020-03-09 | $905.04K 10-K · filed 2019-04-01 |
| 2018-09-30 | $146.79K 10-Q · filed 2019-11-13 | $293.57K derived: sum of 2 quarters · filed 2019-11-13 | $440.86K 10-Q · filed 2019-11-13 | $587.01K derived: sum of 4 quarters · filed 2019-11-13 | |
| 2018-06-30 | $146.79K 10-Q · filed 2019-08-13 | $294.07K 10-Q · filed 2019-08-13 | $440.23K derived: sum of 3 quarters · filed 2019-08-13 | $591.01K derived: sum of 4 quarters · filed 2019-08-13 | |
| 2018-03-31 | $147.29K 10-Q · filed 2019-05-13 | $293.44K derived: sum of 2 quarters · filed 2019-05-13 | $444.23K derived: sum of 3 quarters · filed 2019-05-13 | $596.63K derived: sum of 4 quarters · filed 2019-05-13 | |
| 2017-12-31 | $146.16K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $296.94K derived: sum of 2 quarters · filed 2019-04-01 | $449.34K derived: sum of 3 quarters · filed 2019-04-01 | $608.34K 10-K · filed 2019-04-01 | |
| 2017-09-30 | $150.79K 10-Q · filed 2018-11-09 | $303.19K derived: sum of 2 quarters · filed 2018-11-09 | $462.19K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $152.40K 10-Q · filed 2018-08-09 | $311.40K 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $159.00K 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |